Medical Services

NTRK fusion-positive tumors are a unique group of cancers characterized by genetic alterations in the NTRK (neurotrophic tyrosine receptor kinase) genes, which lead to the production of abnormal TRK fusion proteins that drive tumor growth. These gene fusions are rare but have been identified across a wide spectrum of cancers, often with high prevalence in specific rare tumor types. Notably, NTRK fusions occur in nearly 90–100% of certain rare cancers such as mammary analogue secretory carcinoma (MASC) of the breast and salivary gland, infantile fibrosarcoma, and congenital mesoblastic nephroma. They also appear with lower frequency in more common cancers, including subsets of colorectal, lung, thyroid, and soft tissue tumors.

The presence of NTRK fusions offers a critical target for personalized cancer treatment, as selective TRK inhibitors like larotrectinib and entrectinib have shown remarkable efficacy across these diverse tumor types, regardless of the patient’s age or cancer origin. These therapies represent a groundbreaking "tumor-agnostic" approach by targeting the fusion proteins directly, often leading to durable responses even in advanced or metastatic disease.

Identification of NTRK fusion-positive tumors is vital for guiding treatment and improving outcomes, especially in rare cancers where traditional therapeutic options might be limited. Molecular testing methods, including immunohistochemistry and next-generation sequencing, facilitate the detection of these fusions and enable precision oncology strategies to be implemented effectively.

In summary, NTRK fusion-positive tumors encompass several rare cancer types where these fusions are highly prevalent, offering promising targets for innovative, personalized therapies that improve prognosis and broaden treatment possibilities in oncology.